

15 Jun 2018 | News

QUOTED. June 15, 2018. Riccardo Fruscalzo.

by

There are multiple barriers to personalized medicine development in the EU, including misaligned reimbursement policies between drugs and devices. See what attorney Riccardo Fruscalzo says about it here.

"In Italy, for example, and in many other countries too, the reimbursement process for medicinal products is carried out by different authorities than that for medical devices. This is a problem."
– Riccardo Fruscalzo, counsel, Hogan Lovells

- Find out more: [US And EU Systems For Personalized Medicine: Paths Diverging?](#)

[Click here](#) for a free trial of *Medtech Insight*